<?xml version='1.0' encoding='utf8' standalone='yes'?>
<collection><document><id>25051018</id><infon key="title">CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort.</infon><infon key="pmid">25051018</infon><infon key="pmcid">PMC4160394</infon><infon key="doi">10.1097/FPC.0000000000000079</infon><infon key="year">2014</infon><infon key="month">7</infon><infon key="day">23</infon><infon key="journal">Pharmacogenetics and genomics</infon><infon key="journalISO">Pharmacogenet Genomics</infon><infon key="authors">Joseph P Kitzmiller, Jasmine A Luzum, Damiano Baldassarre, Ronald M Krauss, Marisa W Medina</infon><infon key="chemicals">D002784|Cholesterol	D019821|Simvastatin	C510164|CYP3A5 protein, human	D051544|Cytochrome P-450 CYP3A	C510163|CYP3A4 protein, human</infon><infon key="meshHeadings">Descriptor|D001741|N|African Americans~Qualifier|Q000235|Y|genetics	Descriptor|D002784|N|Cholesterol~Qualifier|Q000097|Y|blood	Descriptor|D015331|N|Cohort Studies	Descriptor|D003460|N|Crystallization	Descriptor|D051544|N|Cytochrome P-450 CYP3A~Qualifier|Q000235|Y|genetics	Descriptor|D044465|N|European Continental Ancestry Group~Qualifier|Q000235|Y|genetics	Descriptor|D005260|N|Female	Descriptor|D056726|N|Genetic Association Studies	Descriptor|D005838|N|Genotype	Descriptor|D006801|N|Humans	Descriptor|D008297|N|Male	Descriptor|D008875|N|Middle Aged	Descriptor|D057566|N|Self Report	Descriptor|D019821|N|Simvastatin~Qualifier|Q000008|N|administration &amp; dosage~Qualifier|Q000097|Y|blood	Descriptor|D014481|N|United States</infon><infon key="supplementaryMesh">None</infon><infon key="publicationTypes">Clinical Trial|Journal Article</infon><passage><infon key="section">title</infon><offset>0</offset><text>CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort.</text><annotation id="T1"><infon key="type">Chemical</infon><infon key="conceptid">MESH:D002784</infon><location offset="104" length="11"/><text>cholesterol</text></annotation><annotation id="T2"><infon key="type">Chemical</infon><infon key="conceptid">MESH:D019821</infon><location offset="70" length="11"/><text>simvastatin</text></annotation><annotation id="T3"><infon key="type">Gene</infon><infon key="conceptid">1577</infon><location offset="14" length="6"/><text>CYP3A5</text></annotation><annotation id="T4"><infon key="type">Gene</infon><infon key="conceptid">1576</infon><location offset="0" length="6"/><text>CYP3A4</text></annotation></passage><passage><infon key="section">abstract</infon><offset>150</offset><text>Simvastatin is primarily metabolized by CYP3A4. A combined CYP3A4/5 genotype classification, combining the decrease-of-function CYP3A4*22 and the loss-of-function CYP3A5*3, has recently been reported. We aim to determine whether CYP3A4*22 and CYP3A5*3 alleles are associated with increased plasma concentrations of simvastatin lactone (SV) and simvastatin acid (SVA). This is the first report evaluating associations between in-vivo simvastatin concentrations and CYP3A4*22, alone or in a combined CYP3A4/5 genotype-defined classification.</text><annotation id="T5"><infon key="type">Chemical</infon><infon key="conceptid">MESH:D019821</infon><location offset="465" length="19"/><text>simvastatin lactone</text></annotation><annotation id="T6"><infon key="type">Chemical</infon><infon key="conceptid">MESH:C063287</infon><location offset="494" length="16"/><text>simvastatin acid</text></annotation><annotation id="T7"><infon key="type">Chemical</infon><infon key="conceptid">MESH:D019821</infon><location offset="583" length="11"/><text>simvastatin</text></annotation><annotation id="T8"><infon key="type">Chemical</infon><infon key="conceptid">MESH:D019821</infon><location offset="150" length="11"/><text>Simvastatin</text></annotation><annotation id="T9"><infon key="type">Gene</infon><infon key="conceptid">1576</infon><location offset="648" length="6"/><text>CYP3A4</text></annotation><annotation id="T10"><infon key="type">Gene</infon><infon key="conceptid">1576</infon><location offset="614" length="6"/><text>CYP3A4</text></annotation><annotation id="T11"><infon key="type">Gene</infon><infon key="conceptid">1577</infon><location offset="393" length="6"/><text>CYP3A5</text></annotation><annotation id="T12"><infon key="type">Gene</infon><infon key="conceptid">1576</infon><location offset="379" length="6"/><text>CYP3A4</text></annotation><annotation id="T13"><infon key="type">Gene</infon><infon key="conceptid">1577</infon><location offset="313" length="6"/><text>CYP3A5</text></annotation><annotation id="T14"><infon key="type">Gene</infon><infon key="conceptid">1576</infon><location offset="278" length="6"/><text>CYP3A4</text></annotation><annotation id="T15"><infon key="type">Gene</infon><infon key="conceptid">1576</infon><location offset="209" length="6"/><text>CYP3A4</text></annotation><annotation id="T16"><infon key="type">Gene</infon><infon key="conceptid">1576</infon><location offset="190" length="6"/><text>CYP3A4</text></annotation><annotation id="T17"><infon key="type">Chemical</infon><infon key="conceptid">MESH:C063287</infon><location offset="512" length="3"/><text>SVA</text></annotation></passage><passage><infon key="section">abstract</infon><offset>689</offset><text>Genotypes and simvastatin concentrations were determined for 830 participants (555 Whites and 275 African-Americans) in the Cholesterol and Pharmacogenomics clinical trial with 40 mg/day simvastatin for 6 weeks. Concentrations were determined in 12-h postdose samples. Associations between simvastatin concentrations and CYP3A4*22 and CYP3A5*3 alleles were tested separately and in a combined CYP3A4/5 genotype-defined classification system.</text><annotation id="T18"><infon key="type">Species</infon><infon key="conceptid">9606</infon><location offset="754" length="12"/><text>participants</text></annotation><annotation id="T19"><infon key="type">Chemical</infon><infon key="conceptid">MESH:D019821</infon><location offset="979" length="11"/><text>simvastatin</text></annotation><annotation id="T20"><infon key="type">Chemical</infon><infon key="conceptid">MESH:D019821</infon><location offset="876" length="11"/><text>simvastatin</text></annotation><annotation id="T21"><infon key="type">Chemical</infon><infon key="conceptid">MESH:D002784</infon><location offset="813" length="11"/><text>Cholesterol</text></annotation><annotation id="T22"><infon key="type">Chemical</infon><infon key="conceptid">MESH:D019821</infon><location offset="703" length="11"/><text>simvastatin</text></annotation><annotation id="T23"><infon key="type">Gene</infon><infon key="conceptid">1576</infon><location offset="1082" length="6"/><text>CYP3A4</text></annotation><annotation id="T24"><infon key="type">Gene</infon><infon key="conceptid">1577</infon><location offset="1024" length="6"/><text>CYP3A5</text></annotation><annotation id="T25"><infon key="type">Gene</infon><infon key="conceptid">1576</infon><location offset="1010" length="6"/><text>CYP3A4</text></annotation></passage><passage><infon key="section">abstract</infon><offset>1130</offset><text>In Whites, CYP3A4*22 carriers (n=42) had 14% higher SVA (P=0.04) and 20% higher SV (P=0.06) compared with noncarriers (n=513). CYP3A5*3 allele status was not significantly associated with SV or SVA in Whites. In African-Americans, CYP3A4*22 carriers (n=8) had 170% higher SV (P&lt;0.01) than noncarriers (n=267), but no significant difference was detected for SVA. African-American CYP3A5 nonexpressors (n=28) had 33% higher SV (P=0.02) than CYP3A5 expressors (n=247), but no significant difference was detected for SVA. For both races, SV appeared to decrease across the rank-ordered combined CYP3A4/5 genotype-defined groups (poor, intermediate, and extensive metabolizers); however, similar trends were not observed for SVA.</text><annotation id="T26"><infon key="type">Gene</infon><infon key="conceptid">1576</infon><location offset="1721" length="6"/><text>CYP3A4</text></annotation><annotation id="T27"><infon key="type">Gene</infon><infon key="conceptid">1577</infon><location offset="1569" length="6"/><text>CYP3A5</text></annotation><annotation id="T28"><infon key="type">Gene</infon><infon key="conceptid">1577</infon><location offset="1509" length="6"/><text>CYP3A5</text></annotation><annotation id="T29"><infon key="type">Gene</infon><infon key="conceptid">1576</infon><location offset="1361" length="6"/><text>CYP3A4</text></annotation><annotation id="T30"><infon key="type">Gene</infon><infon key="conceptid">1577</infon><location offset="1257" length="6"/><text>CYP3A5</text></annotation><annotation id="T31"><infon key="type">Gene</infon><infon key="conceptid">1576</infon><location offset="1141" length="6"/><text>CYP3A4</text></annotation><annotation id="T32"><infon key="type">Chemical</infon><infon key="conceptid">MESH:C063287</infon><location offset="1850" length="3"/><text>SVA</text></annotation><annotation id="T33"><infon key="type">Chemical</infon><infon key="conceptid">MESH:C063287</infon><location offset="1643" length="3"/><text>SVA</text></annotation><annotation id="T34"><infon key="type">Chemical</infon><infon key="conceptid">MESH:C063287</infon><location offset="1487" length="3"/><text>SVA</text></annotation><annotation id="T35"><infon key="type">Chemical</infon><infon key="conceptid">MESH:C063287</infon><location offset="1324" length="3"/><text>SVA</text></annotation><annotation id="T36"><infon key="type">Chemical</infon><infon key="conceptid">MESH:C063287</infon><location offset="1182" length="3"/><text>SVA</text></annotation></passage><passage><infon key="section">abstract</infon><offset>1854</offset><text>Genetic variation in CYP3A4 was associated with plasma simvastatin concentrations in self-reported Whites. Genetic variations in CYP3A4 and CYP3A5 were associated with plasma simvastatin concentrations in self-reported African-Americans.</text><annotation id="T37"><infon key="type">Chemical</infon><infon key="conceptid">MESH:D019821</infon><location offset="2029" length="11"/><text>simvastatin</text></annotation><annotation id="T38"><infon key="type">Chemical</infon><infon key="conceptid">MESH:D019821</infon><location offset="1909" length="11"/><text>simvastatin</text></annotation><annotation id="T39"><infon key="type">Gene</infon><infon key="conceptid">1577</infon><location offset="1994" length="6"/><text>CYP3A5</text></annotation><annotation id="T40"><infon key="type">Gene</infon><infon key="conceptid">1576</infon><location offset="1983" length="6"/><text>CYP3A4</text></annotation><annotation id="T41"><infon key="type">Gene</infon><infon key="conceptid">1576</infon><location offset="1875" length="6"/><text>CYP3A4</text></annotation></passage></document>
</collection>